The University of the Free State (UFS) is on the verge of making history with clinical trials to examine the efficacy of Ivermectin in treating Covid-19.
It is in the process of preparing clinical trial protocol to achieve this. The institution made the announcement on Sunday (24/01).
The work will be undertaken by Farmovs, the university’s wholly owned clinical research company, together with several medical and scientific experts at the university.
The process involves preparing a clinical trial protocol to determine the efficacy of Ivermectin in a randomised, controlled study according to the requirements of the legal professions, in order to submit it for approval to the relevant national regulatory authorities.
Farmovs is a specialty full-service clinical research organisation. Its competitive advantage is its wealth of bioequivalence and phase I clinical trial experience and expertise, patient recruitment success and a clinical research facility with the only onsite International Organization for Standardization (ISO) and Good Laboratory Practice (GLP) certified bioanalytical laboratory on the African continent.
“Should the clinical trial protocol be approved by the relevant national regulatory authority, the UFS will be the first university in South Africa to attempt such a study,” said Dr Nitha Ramnath, spokesperson for the UFS.
She said the UFS was committed to rigorous science and evidence-based research, and both Farmovs and the university fully supported the published opinions and guidelines of the South African Health Products Regulatory Authority (SAHPRA) and the scientific advisory boards established by the scientific community, as well as the stance of the South African government on Ivermectin to treat Covid-19.
